Details

Autor(en) / Beteiligte

• Centofanti, Federica
• Alonzi, Tonino
• Latini, Andrea
• Spitalieri, Paola
• Murdocca, Michela
• Chen, Xiaodong
• Cui, Weibo
• Shang, Qianwen
• Goletti, Delia
• Shi, Yufang
• Duranti, Andrea
• Tomino, Carlo
• Biancolella, Michela
• Sangiuolo, Federica
• Capobianchi, Maria Rosaria
• Jain, Suresh
• Novelli, Giuseppe
• Pandolfi, Pier Paolo

Titel

Indole-3-carbinol in vitro antiviral activity against SARS-Cov-2 virus and in vivo toxicity

Ist Teil von

• Cell death discovery, 2022-12, Vol.8 (1), p.491-491, Article 491

Ort / Verlag

United States: Springer Nature B.V

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• The effects of indole-3-carbinol (I3C) compound have been described deeply as antitumor drug in multiple cancers. Herein, I3C compound was tested for toxicity and antiviral activity against SARS-CoV-2 infection. Antiviral activity was assessed in vitro in both in VeroE6 cell line and human Lung Organoids (hLORGs) where I3C exhibited a direct anti-SARS-CoV-2 replication activity with an antiviral effect and a modulation of the expression of genes implicated in innate immunity and inflammatory response was observed at 16.67 μM. Importantly, we further show the I3C is also effective against the SARS-CoV-2 Omicron variant. In mouse model, instead, we assessed possible toxicity effects of I3C through two different routes of administration: intragastrically (i.g.) and intraperitoneally (i.p.). The LD50 (lethal dose 50%) values in mice were estimated to be: 1410 and 1759 mg/kg i.g.; while estimated values for i.p. administration were: 444.5 mg/kg and 375 mg/kg in male and female mice, respectively. Below these values, I3C (in particular at 550 mg/kg for i.g. and 250 mg/kg for i.p.) induces neither death, nor abnormal toxic symptoms as well as no histopathological lesions of the tissues analysed. These tolerated doses are much higher than those already proven effective in pre-clinical cancer models and in vitro experiments. In conclusion, I3C exhibits a significant antiviral activity, and no toxicity effects were recorded for this compound at the indicated doses, characterizing it as a safe and potential antiviral compound. The results presented in this study could provide experimental pre-clinical data necessary for the start of human clinical trials with I3C for the treatment of SARS-CoV-2 and beyond.